Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder)1. The program is limited to financially eligible patients covered by commercial insurance.
A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.
Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”
+myBinderRelated Content
-
Interview with Dr. Keith Wailoo on the journey of medical and social context in treating sickle cell diseaseKeith Wailoo, Professor of history and p...
-
The 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scie...The Symposium is an exciting three-day m...
-
E.S.C.A.P.E. RetreatE.S.C.A.P.E. (Empowering Sickle Cell Adu...
-
Gary A. GibsonGary A. Gibson has accumulated forty yea...
-
Readout From the First Lady’s Roundtable on Improving the Lives of Americans Living With Sickle Cell DiseaseFirst Lady Melania Trump and the Health ...
-
Piedmont Health Services and Sickle Cell AgencyPiedmont Health Services and Sickle Cell...
-
@juliemakaniScientist|Doctor - Sickle Cell Disease f...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.